(1R,6E,9R,11R,12R,13S,16Z,19S,23R,25R,27R,31S)-27-[tert-butyl(dimethyl)silyl]oxy-11-[(E)-1-iodoprop-1-en-2-yl]-12,31-dimethyl-21-methylidene-4,10,14,29,30-pentaoxa-32-azapentacyclo[23.3.1.12,5.19,13.119,23]dotriaconta-2,5(32),6,16-tetraen-15-one | 867033-48-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 英文名称: (1R,6E,9R,11R,12R,13S,16Z,19S,23R,25R,27R,31S)-27-[tert-butyl(dimethyl)silyl]oxy-11-[(E)-1-iodoprop-1-en-2-yl]-12,31-dimethyl-21-methylidene-4,10,14,29,30-pentaoxa-32-azapentacyclo[23.3.1.12,5.19,13.119,23]dotriaconta-2,5(32),6,16-tetraen-15-one
• CAS: 867033-48-5
• 化学式: C₃₈H₅₆INO₇Si
• 分子量: 793.855
• InChiKey: KRICVZNBWFRKNE-ZCAJQESOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.43
• 重原子数：
  48
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  89.2
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (1R,6E,9R,11R,12R,13S,16Z,19S,23R,25R,27R,31S)-27-[tert-butyl(dimethyl)silyl]oxy-11-[(E)-1-iodoprop-1-en-2-yl]-12,31-dimethyl-21-methylidene-4,10,14,29,30-pentaoxa-32-azapentacyclo[23.3.1.12,5.19,13.119,23]dotriaconta-2,5(32),6,16-tetraen-15-one 在 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 三苯胂 、 四丁基氟化铵 、 N,N-二异丙基乙胺 、 Tetrabutylammoniumsalz der Diphenylphosphinsaeure 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 54.0h， 生成 C₅₃H₇₂N₂O₁₃
  参考文献：
  名称：

  （+）-苯甲唑A的合成研究。一系列高度细胞毒性的C（45-46）类似物的鉴定。

  摘要：

  [结构：见正文]已经实现了六种邻苯二唑A类似物（1-6）的有效，可扩展的总合成和生物学评估。重要的是，饱和的C（45-46），C（45-46）-烯基和C（45-46）-E-氯代烯基同类物（分别为4、5和6）显示出低的纳摩尔肿瘤细胞生长在多种人类癌细胞系中，其抑制活性（GI50）类似于或在某些细胞系中均比邻苯二恶唑更高。

  DOI：

  10.1021/ol051585a
• 作为产物：
  描述：

  (2R,3S,5S,6R)-2-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-6-((E)-2-iodo-1-methyl-vinyl)-3,5-dimethyl-tetrahydro-pyran-4-one 在 氢氧化钾 、 sodium tetrahydroborate 、 15-冠醚-5 、 18-冠醚-6 、 pyridine-SO3 complex 、 三丁基膦 、 四丁基氟化铵 、 potassium hydride 、 碳酸氢钠 、 二甲基氨基丙基乙基碳酰胺 、 potassium carbonate 、 1-羟基苯并三唑 、 戴斯-马丁氧化剂 、 二甲基亚砜 、 三乙胺 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 50.17h， 生成 (1R,6E,9R,11R,12R,13S,16Z,19S,23R,25R,27R,31S)-27-[tert-butyl(dimethyl)silyl]oxy-11-[(E)-1-iodoprop-1-en-2-yl]-12,31-dimethyl-21-methylidene-4,10,14,29,30-pentaoxa-32-azapentacyclo[23.3.1.12,5.19,13.119,23]dotriaconta-2,5(32),6,16-tetraen-15-one
  参考文献：
  名称：

  （+）-苯甲唑A的合成研究。（+）-phorboxazole A的高度收敛的第二代全合成。

  摘要：

  [结构：见正文]已经实现了有效的抗肿瘤药（+）-佛洛他唑A（1）的第二代全合成。这种方法的基石包括一个更趋于收敛的策略，其中包括一个完全精巧的C（1-28）大环与一个C（29-46）侧链的后期Stille并集。第二代合成需要24个步骤的最长线性序列，总产率为4.2％。

  DOI：

  10.1021/ol051584i

文献信息

• Phorboxazole compounds and methods of their preparation
  申请人：The Trustees of the University of Pennsylvania

  公开号：US07485631B2

  公开（公告）日：2009-02-03

  Novel macrolactone compounds, their methods of preparation, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the macrolactone compounds may be useful, inter alia, for treating various cancers, inducing apoptosis in malignant cells, or inhibiting cancer cell division.

  新型大环内酯化合物，其制备方法，含有这些化合物的药物组合物，以及这些药物的药用方法被披露。在某些实施例中，这些大环内酯化合物可能有助于治疗各种癌症，诱导恶性细胞凋亡，或抑制癌细胞分裂。
• Phorboxazole synthetic studies: design, synthesis and biological evaluation of phorboxazole A and hemi-phorboxazole A related analogues
  作者：Amos B. Smith、Anne-Marie L. Hogan、Zhuqing Liu、Thomas M. Razler、Regina M. Meis、Brandon I. Morinaka、Tadeusz F. Molinski

  DOI：10.1016/j.tet.2010.12.043

  日期：2011.7

  evaluation of a new phorboxazole analogue, comprising an acetal replacement for the C-ring tetrahydropyran of the natural product and carrying a potency-enhancing C(45–46) vinyl chloride side chain, is described. In addition, the synthesis of (+)-hemi-phorboxazole A and a series of related hemi-phorboxazole A analogues has been achieved. The new acetal ring replacement analogue displayed activity comparable

  描述了一种新的佛波唑类似物的设计、合成和生物学评价，该类似物包含天然产物C环四氢吡喃的缩醛替代物，并带有增强效力的 C(45-46) 氯乙烯侧链。此外，还实现了(+)-半佛盒唑A和一系列相关的半佛盒唑A类似物的合成。新的缩醛环替代类似物显示出与母体天然产物对 HCT-116（结肠）细胞的活性相当（IC 50 2.25 ng/mL）。同样重要的是，佛盒唑类似物和两个相关的半佛盒唑 A 同源物在针对致病性白色念珠菌菌株进行检测时表现出显着的抗真菌活性。
• A Second-Generation Total Synthesis of (+)-Phorboxazole A
  作者：Amos B. Smith、Thomas M. Razler、Jeffrey P. Ciavarri、Tomoyasu Hirose、Tomoyasu Ishikawa、Regina M. Meis

  DOI：10.1021/jo7018152

  日期：2008.2.1

  A highly convergent second-generation synthesis of (+)-phorboxazole A has been achieved. Highlights of the synthetic approach include improved Petasis-Ferrier union/rearrangement conditions on a scale to assemble multigram quantities of the C(11-15) and C(22-26) cis-tetrahydropyrans inscribed with the phorboxazole architecture, a convenient method to prepare E- and Z-vinyl bromides from TMS-protected alkynes utilizing radical isomerization of Z-vinylsilanes, and a convergent late-stage Stille union to couple a fully elaborated C(1-28) macrocyclic iodide with a C(29-46) oxazole stannane side chain to establish the complete phorboxazole skeleton. The synthesis, achieved with a longest linear sequence of 24 steps, proceeded in 4.6% overall yield.
• Synthesis and Biological Evaluation of Phorboxazole Congeners Leading to the Discovery and Preparative-Scale Synthesis of (+)-Chlorophorboxazole A Possessing Picomolar Human Solid Tumor Cell Growth Inhibitory Activity
  作者：Amos B. Smith、Thomas M. Razler、Regina M. Meis、George R. Pettit

  DOI：10.1021/jo701816h

  日期：2008.2.1

  Highly convergent syntheses of eight phorboxazole congeners and their evaluation against a diverse panel of human solid tumor cancer cell lines have been achieved. Specifically, the C(45-46) alkyne, alkene, and alkane phorboxazole A analogues [(+)-4-(+)-6] were constructed and found to display single digit nanomolar cell growth inhibitory activities in a series of human cancer cell lines. The structurally simplified C(11-15)-acetal congener (+)-20Z also proved potent albeit reduced (cf. 34.6 nM) when evaluated against the same cell line panel. Importantly, (+)-C(46)-chlorophorboxazole A (3) displayed picomolar (pM) inhibitory activity in several cell lines.
• Hemi-Phorboxazole A: Structure Confirmation, Analogue Design and Biological Evaluation
  作者：Amos B. Smith、Zhuqing Liu、Anne-Marie L. Hogan、Doralyn S. Dalisay、Tadeusz F. Molinski

  DOI：10.1021/ol9014317

  日期：2009.8.20

  A synthesis providing totally synthetic (+)-hemi-phorboxazole A (1), proceeding in two steps (85% yield) from known vinyl iodide precursor (+)-2, has been achieved in conjunction with the design, synthesis, and biological evaluation of two hemi-phorboxazole analogues [(+)-3 and (-)-4] featuring ring replacements inscribed within the macrolide. Although hemi-phorboxazole A (1) displayed no activity when tested against Candida albicans and two human cancer cell lines, analogue (-)-4 exhibited significant tumor cell growth inhibitory activity in the nanomolar range against HCT-116 (colon) and SK-BR-3 (breast), while (+)-3 displayed promising antifungal activity against C. albicans.